In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).